NASDAQ: CTKB · Medical Devices

Cytek Biosciences (CTKB) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Cytek Biosciences (CTKB) at $6.03 a share. The stock last closed at $5.63, which puts the model's fair value 7.1% above the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Cytek Biosciences, Inc.

The report adds the live price, the price chart, the next earnings date and the analysts' consensus. No account needed.

Model fair value$6.03midpoint of 2,000 simulations
Last close$5.63NASDAQ: CTKB
Gap to fair value+7.1%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $7.23 to $6.03 (-16.6%). The multiple the model anchors on moved, lowering the fair value: most of the move.

What the model makes of itThe price of $5.63 is 7.1% below it: Fairly valued, on a medium evidence grade.

What's nextNext report on 25 Feb 2027. On the model's Scorecard Leaders list since 12 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give CTKB?

The calibrated range for CTKB over 63 trading days is $4.82 to $7.16. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $4.95 to $7.21. In 55% of the simulations the fair value came out above the price the model ran on.

$3.88$9.56
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $6.03. Dashed line: the last close, $5.63.

Faircurve Insights · 14 Nov 2026

Cytek Biosciences, Inc. (CTKB) is a company dedicated to cell analysis solutions. It offers advanced tools for biomedical research and clinical settings.

Faircurve's model put the fair value at $6.03 a share on 14 Nov 2026. The previous run, on 7 Nov 2026, gave $7.23, so the fair value moved -16.6%. The reason, in the model's words: "The multiple the model anchors on moved, lowering the fair value: most of the move." The calibrated range over 63 trading days is $4.82 to $7.16. With no live options data, the range is built from the fair value. It is calibrated weekly against realised prices, using 13,250 past valuations, refreshed the same day. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. It looks at input completeness, comparables and outcome spread. It does not say whether the fair value is right.

Cytek Biosciences scores 46 out of 100 on the model's overall quality score, a composite of six factors scored against comparable companies. Stability is the highest at 71, with five-year EBITDA margin downside volatility of 4.5 pts against a peer median of 25.1 pts. Profitability scores 30, with ROIC at -15.7% against a peer median of -2.0%. The model compares the company with Artivion, Inc. (AORT), Integra LifeSciences Holdings Corporation (IART), Enovis Corporation (ENOV) and UFP Technologies, Inc. (UFPT).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does CTKB report earnings, and how has the stock reacted?

Cytek Biosciences's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CTKB's last 8 reports, ignoring direction, was 8.0%.

0%10%20%30%40%no quote42.3%5 Nov '24no quote10.2%27 Feb '25no quote5.9%6 Aug '25no quote16.1%5 Nov '25no quote2.5%26 Feb '26no quote6.7%7 May '26no quote2.8%5 Aug '26no quote9.4%4 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

How does CTKB score on business quality?

Cytek Biosciences's overall quality score is 46 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.30-15.7%ROIC-2.0%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).70
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.310.5%Revenue growth, trailing1.0%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.620.0%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.361.42xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.714.5 ptsEBITDA margin downside volatility, 5y25.1 pts

How does CTKB compare with similar companies?

The companies in medical devices closest to Cytek Biosciences in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
AORT Artivion, Inc.$18.47$20.28+9.8%Fairly valued
AHCO AdaptHealth Corp.$7.73$7.47-3.4%Low evidence grade
IART Integra LifeSciences Holdings Corporation$13.98$16.00+14.4%Fairly valued
TNDM Tandem Diabetes Care, Inc.$18.48$21.89+18.5%Low evidence grade
CNMD CONMED Corporation$49.35$50.43+2.2%Low evidence grade
ENOV Enovis Corporation$27.92$32.77+17.4%Undervalued
INSP Inspire Medical Systems, Inc.$59.12$61.27+3.6%Low evidence grade
UFPT UFP Technologies, Inc.$298.54$266.65-10.7%Fairly valued

What the comparable companies' multiples alone would give for CTKB, the peer-implied price, is $6.92 a share on this run. The fair value weighs that against the company's own multiple.

All medical device stocks ranked by gap to fair value

Cytek Biosciences at a glance

Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings.

Market value
$764M
Sector
Healthcare
Industry
Medical Devices
Revenue expected, next twelve months
$221M
Consensus revenue growth, next fiscal year
+3.8%
Analysts with estimates
2
Beta to the US market
1.02
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. CTKB was among them.

How the fair value is worked out: the model prices Cytek Biosciences on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for CTKB was $7.23. As of 14 Nov 2026 it is $6.03, a change of -16.6%. The multiple the model anchors on moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Cytek Biosciences's valuation

Is Cytek Biosciences stock undervalued or overvalued?

On Faircurve's model, CTKB reads as Fairly valued as of 14 Nov 2026. The model's fair value is $6.03 a share against a last close of $5.63, a gap of +7.1%.

What is CTKB's fair value?

$6.03 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $4.95 to $7.21.

What price range does the model give CTKB?

$4.82 to $7.16 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.

When does Cytek Biosciences report earnings next?

The next report is scheduled for 25 Feb 2027. Companies can move their dates.

How much has CTKB moved on past earnings reports?

Across its last 8 reports the median two session move was 8.0%, ignoring direction. The largest was +42.3% around the report of 5 Nov 2024.

How confident is the model in this valuation?

The model's evidence grade for CTKB is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on CTKB

The model has an idea open on CTKB under Scorecard Leaders since 12 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CTKB with their outcomes. A free account is enough.

Keep reading